Persistent pulmonary hypertension of the newborn (PPHN) is a serious condition in which a baby’s blood circulation fails to make its normal switch from the fetal pattern to independent breathing after birth. It occurs in roughly 1 to 2 out of every 1,000 live births, most often in full-term or post-term infants. The result is dangerously low oxygen levels that require urgent treatment in a neonatal intensive care unit.
How a Newborn’s Circulation Normally Changes
Before birth, a baby’s lungs are filled with fluid and do almost no work. Oxygen comes from the placenta, and most blood bypasses the lungs entirely through two shortcuts: a small opening between the upper heart chambers (the foramen ovale) and a short vessel connecting the two major arteries (the ductus arteriosus). Resistance in the lung blood vessels is kept deliberately high so blood flows around them.
At birth, several things happen in quick succession. The umbilical cord is clamped, removing the low-resistance placenta from the circuit and raising the baby’s overall blood pressure. The baby takes its first breaths, the lungs inflate with air, and oxygen floods the lung tissue. This causes the lung blood vessels to relax and open wide. Blood flow through the lungs increases roughly eightfold within minutes. The surge of returning blood raises pressure on the left side of the heart, closing the foramen ovale. As lung resistance drops below body resistance, blood reverses direction through the ductus arteriosus, which soon closes on its own.
What Goes Wrong in PPHN
In PPHN, lung blood vessel resistance stays high after birth instead of dropping. Because the pressure in the lungs remains elevated, blood continues to shunt through those fetal shortcuts, bypassing the lungs just as it did before delivery. Oxygen-poor blood mixes back into the general circulation, and the baby becomes severely oxygen-deprived despite breathing on its own or with ventilator support.
There are several reasons the lung vessels may fail to open up. Sometimes the vessels are structurally normal but remain tightly constricted. In other cases, the vessel walls have thickened during fetal development, physically narrowing the passages. Tiny blood clots can block the vessels from the inside. And in some babies, the lungs themselves are underdeveloped, leaving too few blood vessels to carry adequate flow regardless of how relaxed they are.
Conditions That Trigger PPHN
PPHN rarely appears out of nowhere. It is usually triggered by an underlying problem that interferes with normal lung function at birth. Meconium aspiration syndrome, where the baby inhales stool-contaminated amniotic fluid, is one of the most common triggers. Among infants cooled for moderate to severe oxygen deprivation at birth, roughly 23 to 25% develop PPHN, and that number rises to 39% when meconium aspiration is also present. Other triggers include pneumonia, respiratory distress syndrome, and congenital diaphragmatic hernia, where abdominal organs push into the chest and crowd the lungs.
A smaller number of cases are considered idiopathic, meaning no clear lung disease is found. In these babies, the pulmonary blood vessels appear to have remodeled abnormally before birth, leaving them resistant to the normal signals that should open them up.
Prenatal Risk Factors
Certain maternal factors raise the likelihood of PPHN. Maternal diabetes roughly doubles the risk. Higher maternal age is an independent risk factor as well, though the increase per year is modest. Use of SSRI antidepressants during the second half of pregnancy is associated with roughly four times the odds of PPHN compared to not using antidepressants, even after accounting for the underlying depression. Notably, SSRI use before 20 weeks of pregnancy does not carry this association, and a related class of antidepressants (SNRIs) has not shown the same statistical link, though studies on SNRIs have been small.
Use of certain over-the-counter pain relievers late in pregnancy, particularly nonsteroidal anti-inflammatory drugs like ibuprofen, has also been linked to premature narrowing of the ductus arteriosus, which can set the stage for PPHN.
Signs and Symptoms
The hallmark of PPHN is cyanosis, a bluish discoloration of the skin, that appears within hours of birth and responds poorly to supplemental oxygen. What often distinguishes PPHN from a heart defect is differential cyanosis: the baby’s right hand (which receives blood pumped before the ductus arteriosus) may have noticeably higher oxygen levels than the feet (which receive blood after the shunt). This gap between “pre-ductal” and “post-ductal” oxygen readings is a classic clue.
Babies with PPHN also typically breathe fast, grunt with each breath, and may have retractions where the skin pulls in around the ribs. Oxygen levels can swing dramatically, sometimes dropping with minimal handling or stimulation and partially recovering when the baby is left alone. This lability, where oxygen readings are unpredictable and hard to stabilize, is characteristic.
How PPHN Is Diagnosed
Echocardiography is the primary diagnostic tool. An ultrasound of the heart can directly visualize the fetal shunts, measure the speed of blood leaking backward through the tricuspid valve, and estimate the pressure in the pulmonary artery. In studies of PPHN outcomes, estimated systolic pulmonary pressures of 60 to 75 mmHg have been common at diagnosis. The echo also rules out structural heart defects that can mimic PPHN.
Doctors classify the severity based on whether the estimated pulmonary pressure is below, equal to, or above the baby’s systemic blood pressure. When pulmonary pressure exceeds systemic pressure (supra-systemic), the shunting is at its worst and the situation is most urgent. The difference between pre-ductal and post-ductal oxygen readings, monitored continuously with pulse oximeters on the right hand and a foot, provides real-time tracking of how much blood is bypassing the lungs.
Treatment in the NICU
Treatment focuses on lowering lung vessel resistance, supporting blood pressure, and ensuring adequate oxygen delivery. The first steps are mechanical ventilation and careful oxygen management. Keeping the pre-ductal oxygen saturation above 95% is a common target. Gentle ventilation strategies are preferred because aggressive settings can damage fragile lungs and worsen the problem.
Inhaled nitric oxide is the most established targeted therapy. Delivered directly into the lungs through the ventilator circuit at a standard dose of 20 parts per million, it selectively relaxes pulmonary blood vessels without dropping blood pressure in the rest of the body. Higher doses are not recommended because they don’t improve outcomes and increase the risk of side effects.
When inhaled nitric oxide alone isn’t enough, additional medications can help. Sildenafil, given orally, works through a different pathway to relax the lung vessels. Milrinone, given intravenously, both relaxes the vessels and strengthens the heart’s pumping ability. A randomized trial found that combining these two medications produced significantly lower pulmonary pressures and better oxygenation than either drug alone, with reduced mortality in the combination group.
When More Intensive Support Is Needed
For the most severe cases that don’t respond to medication, extracorporeal membrane oxygenation (ECMO) may be considered. ECMO is essentially a heart-lung bypass machine: blood is drawn out of the baby’s body, oxygen is added and carbon dioxide removed by the machine, and the blood is returned. It buys time for the lungs to heal and the pulmonary vessels to relax on their own.
ECMO is typically considered when the oxygenation index, a calculation combining ventilator settings and blood oxygen levels, reaches 40 or higher and stays there for four or more hours. PPHN is the single most common reason newborns are placed on ECMO. Not every hospital has ECMO capability, so babies who are trending in that direction may need to be transferred to a specialized center.
Survival and Long-Term Outcomes
Survival rates for PPHN vary widely depending on severity, underlying cause, and available treatment. Reported mortality ranges from 11% to 48% across studies, with milder cases and those responsive to inhaled nitric oxide faring considerably better. Access to ECMO has improved survival for the most critical infants.
Among survivors, the majority develop normally, but a meaningful percentage face lasting challenges. Studies following babies treated for PPHN have found major neurological abnormalities in about 13% by one year of age, cognitive delays in up to 30%, and hearing loss in roughly 19%. Severe neurodevelopmental disability has been documented in about 12% of survivors by age two. The numbers improve in studies of moderately affected infants: one follow-up found only a 6.7% rate of adverse outcomes at three years among those with moderate disease.
Behavioral problems and language difficulties also appear at higher rates in PPHN survivors assessed during toddler and preschool years, with some studies reporting behavioral concerns in about 26% and language disturbances in 22% of children assessed around age three. These findings underscore why follow-up developmental screening in the first few years is standard for babies who have been treated for PPHN.